We previously identified a 25-year-old man with AML (FAB M1) and a novel translocation that was initially described as a t(4;9)(q13;q34) by standard cytogenetic analysis but was subsequently revised to t(4;9)(q11;q33) following spectral karyotyping. The presence of BCR-ABL and DEK-CAN mRNA transcripts were both excluded by To characterize the translocation in more detail, we initially performed split-apart interphase fluorescence in situ hybridization (FISH) analysis for genes that are known to be translocation targets in myeloid neoplasia. No rearrangements were seen with probes that flanked ABL at 9q34 or PDGFRA at 4q12; 5 however, split signals (not shown) were seen with bacterial artificial chromosome (BAC) clones RP11-525G7 and RP11-477J21 that were selected to flank CEP110, a gene encoding a centrosomal protein that is fused to FGFR1 in the 8p11 myeloproliferative syndrome with a t(8;9)(p12;q33). 6 Hypothesizing that the fusion partner was likely to be a tyrosine kinase, we next performed split apart FISH for the two other RTKs located at 4q12. No rearrangement was seen for KDR, but split signals were seen for KIT using BACs RP11-80L11 and RP11-273B19 (not shown).
Systemic mastocytosis (SM) may be associated in up to 30% with a non-mast cell haematological disease leading to the separation of a peculiar subtype designated SM with associated haematological non-mast cell disease, which is commonly a Philadelphia chromosome/BCR-ABL-negative (Ph À ) myeloid neoplasm. 1 Criteria for the diagnosis of SM comprise one major finding (compact infiltrates consisting of 415 clustered mast 
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CTC CGA GAG TTA GAG AAA AAG ccc atg tat gaa gta cag Figure 1 (a) RT-PCR with a forward primer in CEP110 (5 0 -TCTCAGTGCCTATGAAGCTGAGC-3 0 ) and a reverse primer in KIT (5 0 -TCTCAGTGCCTATGAAGCTGAGC-3 0 ) yielded a specific 1650-bp product from a pretreatment peripheral blood sample from the t(4;9) case (P1) that was not seen in two control individuals (N1, N2) or blank reactions (B1, B2). (b) In-frame mRNA fusion between CEP110 exon 19 and KIT exon 11.
Letters to the Editor cells) and four minor findings (prominent spindling of mast cells with at least 25% spindle forms within a compact infiltrate, aberrant expression of CD25 or CD2 by mast cells, activating point mutation in exon 17 of the stem cell factor KIT codon 816, usually codon 816/KIT D816V and chronically elevated serum tryptase levels). 1 Altogether, the major and one minor criterion or at least three minor criteria have to be fulfilled for a diagnosis of SM to be established.
The association of SM with Philadelphia chromosome/BCR-ABL-positive (Ph þ ) chronic myelogenous leukaemia (CML) appears to be very rare. Only two case have been reported. 2, 3 In only one of these two cases, KIT mutation status, clinical characteristics and follow-up were available. 2 Ph þ CML is morphologically characterised by hyperproliferation of maturing granulocytopoiesis and scattered micromegakaryocytes. Co-existence of CML and a non-CML neoplastic proliferation of myeloid origin is very rare. 4, 5 A few cases of Ph þ CML with Ph À /JAK2 V617F myeloproliferative neoplasms (MPN) have been described. 4 CML can be suppressed by the BCR-ABL inhibitor imatinib mesylate (IM). In CML, secondary ABL mutations mediate an IM resistance, whereas KIT D816V is usually not sensitive to IM. 1 In this analysis, a total of 98 formalin-fixed and paraffinembedded (FFPE) bone marrow samples from 95 patients were evaluated by immunohistochemistry; in addition to a SM-CML case (one initial biopsy and three follow-up biopsies), for control purposes, 81 Ph þ CML and 13 Ph À primary myelofibrosis (PMF) clinical bone marrow samples were analysed. All samples were retrieved from the archives of the Institute of Pathology (Hannover Medical School). The retrospective evaluation had been approved by the local Ethics Committee.
In this study, we present the third documented case of SM-CML presenting with some unusual phenotypic and genotypic findings and emphasising the usefulness of immunohistochemical markers for diagnosis. A detailed case presentation is provided in Supplementary Table 1. In brief, the bone marrow of the present case on the one hand exhibited the typical features of CML including prominent proliferation of maturing neutrophilic myelopoiesis, scattered micromegakaryocytes and the BCR-ABL translocation (follow-up analysis revealed cytogenetic evolution with an additional Ph þ , isoderivative Ph þ and trisomy of chromosome 17 within the Ph þ clone). On the other hand, SM was diagnosed by demonstration of multifocal dense infiltrates consisting of spindle-shaped mast cells (thus the major and one minor criteria for diagnosis of SM were fulfilled). The SM could easily be visualised by tryptase immunostaining but was hardly detectable in conventional hematoxylin and eosin or Giemsa-stained sections. Moreover, a further minor diagnostic criterion was found, that is, aberrant expression of CD25 by intramedullary mast cells (Figures 1a-d) . CD25, the interleukin 2 receptor alpha, is expressed only on neoplastic but not on normal or reactive mast cells and therefore it is considered to be a surrogate marker of neoplastic mast cell proliferations. 1 The mast cells also revealed a strong expression of CD117 (KIT protein), thus, fulfilling the minimal criteria for cells to be identified as mast cells, that is, co-expression of tryptase and KIT. Surprisingly, the KIT D816V -activating point mutation, the most frequent mutation associated with SM, 1 and other exon 17 mutation were not detectable in laser-microdissected mast cells (Figure 1e ; Supplementary Figure 1 and Supplementary Table 2 ). Altogether, lack of KIT D816V is seen in less than 5% of SM cases when sensitive molecular methods are applied. 1 In SM-Ph À MPN (SM-PMF) it has been shown that the mast cells and granulocytic cells originate from the same aberrant JAK2 V617F progenitor. 6 In our case of SM-CML, the fluorescence in situ hybridisation of FFPE sections (FFPE-FISH analysis) revealed no clonal relationship between the Ph þ /trisomy 17-positive leukaemic clone (leucocytes and megakaryocytes) and mast cells (Figures 1f-k) . It cannot be excluded, however, that mast cells belong to a hypothetical pre-Ph þ aberrant progenitor/stem cell clone. It is thought that in CML at least 1-2 mutations might precede the Ph þ translocation. 7 Similar to the previously presented SM-CML case, 2 the concomitant SM was present from the initial time point of CML diagnosis but was obscured by the leukaemic proliferation with focal fibrosis and therefore detected only retrospectively. Fibrosis is not uncommon in CML and can be found in about 20% of cases. 5 Immunohistochemistry immediately unmasked the dense focal mast cell infiltrates within the desmoplastic matrix. Owing to its rarity, a systematic evaluation of concomitant SM in Ph þ CML cannot be recommended. To be sure of this finding and to obtain more information on its incidence, we therefore analysed a representative number of MPN cases using tryptase as a screening marker (Supplementary  Table 3 ). However, it was not possible to identify any other case of SM-Ph þ CML. Interestingly, tryptase-positive/KIT-negative basophilic granulocytes were detected in larger numbers in a minority of these cases. It is important to discriminate these loosely scattered small round tryptase-positive cells from findings called tryptase-positive round cell infiltration of the bone marrow. 3 It comprises a limited panel of rare haematological neoplasms including well-differentiated SM, myelomastocytic leukaemia and basophilic leukaemia. Tryptase-positive but KIT-negative cells are either basophils or myeloblasts. Myelofibrosis before the background of CML is per se not a diagnostic hint for a concomitant SM, but focal fibrosis may obscure a co-existing mast cell infiltrate. Tryptase-positive/ KIT-negative/CD25-negative basophils might be present in Ph þ and Ph À MPN, but can easily be discriminated from aberrant mast cells by histomorphology.
An undesirable side effect of the potent tyrosine kinase suppression in at least 10% of IM-treated Ph þ CML patients appears to be the evolution towards additional cytogenetic aberrations other than the initial Ph þ translocation. 8 The most frequent aberrations are trisomy of chromosome 8 or monosomies of chromosomes 7 and Y. These secondary cytogenetic aberrations appear to be associated either with (1) persistent CML, (2) therapy-related hypoplastic or transient variants of the myelodysplastic syndromes, (3) a secondary acute leukaemia, (4) occasional fibrosis or with (5) no phenotypically detectable haematological disorders. 5, 8 In the present case, the Ph þ clonality showed cytogenetic evolution but no secondary IM resistance-mediating BCR-ABL mutations and was associated with the persistence of the CML phenotype. Because the original Ph þ clone proliferated in parallel to its subclones, other additional subchromosomal mutations are likely. The secondary cytogenetic aberrations within the Ph þ clone might be additional reasons for therapy failure. Regarding IM, KIT D816V is a resistance-mediating mutation but, nevertheless, complete haematological remission has been achieved in the previously reported KIT D816V SM-Ph þ CML case. 2 In this KIT D816V -negative case, the SM persisted despite several myelosuppressive agents at a constant level of 5-10% of bone marrow cellularity. Other rare KIT exon 17 alterations were not found (Figure 1e ), indicating that other unknown genetic defects might have been associated with this chemotherapy resistance of the mast cells.
In conclusion, bone marrow evaluation of a CML might incidentally reveal the concomitant presence of an SM in terms of an extremely rare SM with associated haematological nonmast cell disease, thus representing SM-Ph þ CML.
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The authors declare no conflict of interest. Table 2 . (f-k) Mast cell compartments were identified in FFPE-FISH analysis by dense paratrabecular infiltrates consisting of elongated cells with ovoid nuclei and autofluorescence of loose cytoplasmic granules (f, h, i; all images and inserts Â 1000). Basophils and eosinophils exhibited a strong autofluorescence of the abundant cytoplasmic granules and could not be evaluated. The autofluorescence made the evaluation difficult but in some mast cells clearly wildtype signals were detectable (f). Thus, the normal BCR and ABL signals (f), as well as the normal numerical configuration of chromosome 17 (I) indicates that neoplastic mast cells neither belong to the initial Ph þ clone nor to the þ 17 subclone, which emerged from the Ph þ clone. FFPE-FISH confirmed the results of the conventional cytogenetics and showed a BCR-ABL fusion signal (g) and three centromere 17 signals (j, k) in bone marrow non-mast cell round leucocytes without cytoplasmic granules (g, j) and megakaryocytes (k). Histological/immunohistochemical and FFPE-FISH images have been produced with a DP71 Camera, (Olympus, Hamburg, Germany) on an Axiophot microscope with a Plan-Neofluar Â 20/0.50 objective (both Zeiss, Jena, Germany) and a B Â 51 fluorescence microscope with a UPlan FI Â 100/1.30 oil objective (Olympus), respectively.
